{"prompt": "['2016N293064_03', 'CONFIDENTIAL', '2018N394263_0', '205864', 'Amended text:', 'Appendix 5: Contraceptive Guidance and Collection of Pregnancy', 'Information', 'Definitions', 'Woman of Childbearing Potential (WOCBP)', 'A woman is considered fertile following menarche and until becoming post-menopausal', 'unless permanently sterile (see below)', 'Women in the following categories are not considered WOCBP', '1. Premenarchal', '2.', 'Premenopausal female with ONE of the following:', 'Documented hysterectomy', 'Documented bilateral salpingectomy', 'Documented bilateral oophorectomy', \"Note: Documentation can come from the site personnel's: review of participant's\", 'medical records, medical examination, or medical history interview.', '3.', 'Postmenopausal female', 'A postmenopausal state is defined as no menses for 12 months without an', 'alternative medical cause. A high follicle stimulating hormone (FSH) level in', 'the postmenopausal range may be used to confirm a postmenopausal state in', 'women not using hormonal contraception or hormonal replacement therapy', '(HRT). However, in the absence of 12 months of amenorrhea, a single FSH', 'measurement is insufficient and confirmatory testing with additional FSH and', 'estradiol measurements is required.', 'Females on HRT and whose menopausal status is in doubt will be required to', 'use one of the non-hormonal highly effective contraception methods if they wish', 'to continue their HRT during the study. Otherwise, they must discontinue HRT', 'to allow confirmation of postmenopausal status before study enrollment.', '113']['2016N293064 0', 'CONFIDENTIAL', '2018N394263_00', 'GlaxoSmithKline group of companies', '205864', 'TITLE PAGE', 'Protocol Title: A randomized, double-blind, Sponsor open, placebo-controlled, 52 week', 'study evaluating the effect of danirixin (GSK1325756) on lung function and health', 'related quality of life in participants with mild to moderate Chronic Obstructive', 'Pulmonary Disease (COPD).', 'Protocol Number: 205864 Amendment 2', 'Short Title: Danirixin Pilot Study for Disease Progression', 'Compound Number: GSK1325756', 'Sponsor Name and Legal Registered Address:', 'GlaxoSmithKline Research & Development Limited', '980 Great West Road', 'Brentford', 'Middlesex, TW8 9GS', 'UK', 'Medical Monitor Name and Contact Information will be provided in the Study', 'Reference Manual', 'Regulatory Agency Identifying Number(s) IND:108168', 'Approval Date: 24-JUL-2017', 'Copyright 2017 the GlaxoSmithKline group of companies. All rights reserved.', 'Unauthorised copying or use of this information is prohibited.', '1']['2016N293064_02', 'CONFIDENTIAL', '2018N394263 00', '205864', 'SPONSOR SIGNATORY:', 'PPD', '24 July 2017', 'Aili Lazaar, MD', 'PPD', 'Date', 'Clinical Development Director', 'Respiratory Therapy Are Unit', 'PPD', '2']\n\n###\n\n", "completion": "END"}